Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
91-105 of 4525 results
Domainex, Imperial College London expand cardiac therapy collaboration
Domainex has extended its partnership with Imperial College London to discover novel therapies that reduce heart muscle damage during heart attacks.
Drug Research > Drug Discovery & Development > News
Omeros’ OMS721 kidney drug gets FDA breakthrough therapy status
By PBR Staff Writer
Omeros’ MASP-2 inhibitor OMS721 has secured breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of Immunoglobulin A (IgA) nephropathy.
Drug Research > Drug Discovery & Development > News
Selexis, TeneoBio sign deal to advance development of UniAbs targeting cancer
Selexis and TeneoBio have signed a service agreement to jointly advance the development of a new class of biologics, Human Heavy-Chain Antibodies (UniAbs) targeting cancer.
Drug Research > Drug Discovery & Development > News
Numerate, Takeda partner to generate clinical candidates using AI-driven drug discovery
Numerate has entered into a multi-year agreement with Takeda Pharmaceutical under which it will identify and deliver multiple clinical candidates by applying artificial intelligence (AI) at cloud scale.
Drug Research > Drug Discovery & Development > News
EC approves Johnson & Johnson's $30bn acquisition of Actelion
By PBR Staff Writer
The European Commission (EC) has approved Johnson & Johnson's proposed $30bn acquisition of Actelion Pharmaceuticals, subject to conditions
Drug Research > Drug Discovery & Development > News
Midatech signs deal with Novartis to investigate panobinostat to treat brain cancers
Midatech Pharma has inked a global licensing agreement with Novartis for the oncology compound panobinostat.
Drug Research > Drug Discovery & Development > News
GL Capital-led consortium to buy SciClone Pharmaceuticals
A consortium featuring entities affiliated with GL Capital Management GP, Bank of China Group Investment (BOCGI), CDH Investments, Ascendent Capital Partners and Boying will acquire all the outstanding shares of SciClone Pharmaceuticals for $11.18 per share in cash.
Drug Research > Drug Discovery & Development > News
Eleven Biotherapeutics to collaborate with Astrazeneca, National Cancer Institute
Eleven Biotherapeutics signed a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to assess its late-clinical-stage fusion protein Vicinium (VB4-845) combined with AstraZeneca’s immune checkpoint inhibitor Imfinzi (durvalumab) to treat nonmuscle invasive bladder cancer (NMIBC).
Drug Research > Drug Discovery & Development > News
AbCellera partners with Sanofi Pasteur to advance influenza vaccine research
AbCellera has partnered with Sanofi Pasteur to advance the research and development of next-generation influenza vaccines.
Drug Research > Drug Discovery & Development > News
Carlyle, GTCR to buy Albany Molecular Research for $922m
By PBR Staff Writer
The Carlyle Group and GTCR have agreed to acquire global contract research and manufacturing organization, Albany Molecular Research (AMRI), for around $922m.
Drug Research > Drug Discovery & Development > News
Sevion to acquire Eloxx Pharmaceuticals
Sevion Therapeutics has agreed to acquire Eloxx Pharmaceuticals, which is focused on developing therapeutics for genetic diseases caused by non-sense mutations.
Drug Research > Drug Discovery & Development > News
Scientists at Scripps Research Institute make Lassa virus vaccine breakthrough
Scientists at Florida’s The Scripps Research Institute (TSRI) have succeeded in modeling a key part of a virus that sickens several people in West Africa.
Drug Research > Drug Discovery & Development > News
Eisai and Charles River Laboratories extend drug discovery collaboration
Eisai and Charles River Laboratories International have agreed to extend their two-year collaboration in integrated drug discovery for another year.
Drug Research > Drug Discovery & Development > News
Sunovion receives complete response letter from FDA for SUN-101/eFlow for COPD
Sunovion Pharmaceuticals has received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA) for the New Drug Application (NDA) for SUN-101/eFlow (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), such as chronic bronchitis and/or emphysema.
Drug Research > Drug Discovery & Development > News
Merck licenses Teijin Pharma's Alzheimer's candidate
Merck has signed a worldwide license agreement with Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical antibody candidate targeting the protein tau.
Drug Research > Drug Discovery & Development > News
91-105 of 4525 results